Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury

Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase. It was approved by the Food and Drug Administration for the treatment of intermittent claudication. Its principal actions include inhibition of platelet aggregation, antith...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:CNS Neurosci Ther
Päätekijät: Lee, Jeong Hyun, Park, So Youn, Shin, Hwa Kyoung, Kim, Chi Dae, Lee, Won Suk, Hong, Ki Whan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Inc 2008
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494013/
https://ncbi.nlm.nih.gov/pubmed/18482026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2008.00042.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia